{"title":"[Platform technologies in vaccine development].","authors":"Eberhard Hildt","doi":"10.1007/s00103-025-04024-6","DOIUrl":null,"url":null,"abstract":"<p><p>Platform technologies in the narrower sense refer to approaches to vaccine development in which the vaccine is always based on a consistently identical framework and differs only in terms of the antigen. One advantage of platform technologies is their rapid adaptability for the development of a vaccine against novel pathogens or variants. Currently approved vaccines in the EU use viral vectors and mRNA as platforms. Recombinant adenoviruses (Ad), vesicular stomatitis virus (VSV), and modified vaccinia virus Ankara (MVA) serve as viral vectors. The application of mRNA-based vaccines is carried out in the form of lipid nanoparticles (LNPs). The function of the LNPs is to protect the mRNA from degradation, promote the uptake of the mRNA into the cells, and provide an adjuvant effect.</p>","PeriodicalId":9562,"journal":{"name":"Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz","volume":" ","pages":"368-377"},"PeriodicalIF":1.7000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11950034/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00103-025-04024-6","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/4 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}
引用次数: 0
Abstract
Platform technologies in the narrower sense refer to approaches to vaccine development in which the vaccine is always based on a consistently identical framework and differs only in terms of the antigen. One advantage of platform technologies is their rapid adaptability for the development of a vaccine against novel pathogens or variants. Currently approved vaccines in the EU use viral vectors and mRNA as platforms. Recombinant adenoviruses (Ad), vesicular stomatitis virus (VSV), and modified vaccinia virus Ankara (MVA) serve as viral vectors. The application of mRNA-based vaccines is carried out in the form of lipid nanoparticles (LNPs). The function of the LNPs is to protect the mRNA from degradation, promote the uptake of the mRNA into the cells, and provide an adjuvant effect.
期刊介绍：
Die Monatszeitschrift Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz - umfasst alle Fragestellungen und Bereiche, mit denen sich das öffentliche Gesundheitswesen und die staatliche Gesundheitspolitik auseinandersetzen.
Ziel ist es, zum einen über wesentliche Entwicklungen in der biologisch-medizinischen Grundlagenforschung auf dem Laufenden zu halten und zum anderen über konkrete Maßnahmen zum Gesundheitsschutz, über Konzepte der Prävention, Risikoabwehr und Gesundheitsförderung zu informieren. Wichtige Themengebiete sind die Epidemiologie übertragbarer und nicht übertragbarer Krankheiten, der umweltbezogene Gesundheitsschutz sowie gesundheitsökonomische, medizinethische und -rechtliche Fragestellungen.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
